Minerva Posts Q2 Profit on Non-Cash Warrant Gain; C19 Trial Enrollment Underway

summarizeSummary

Minerva Neurosciences reported a Q2 2026 GAAP profit of $17.5 million driven by a non-cash warrant liability gain, while its pivotal C19 trial for roluperidone is now enrolling patients. Cash of $75.4 million provides a 12-month runway.

check_boxKey Events · Earnings and Guidance · NERV

• Q2 GAAP Profit Driven by Non-Cash Gain

  Net income of $17.5 million in Q2 2026 resulted from a $27.6 million non-cash gain on the revaluation of warrant liabilities, masking an operating loss of $10.6 million.

• Cash Runway at 12 Months

  Cash, equivalents, and marketable securities totaled $75.4 million as of June 30, 2026, which management expects to fund operations for at least the next 12 months.

• C19 Pivotal Trial Enrolling

  The confirmatory Phase 3 C19 trial for roluperidone screened its first patient on March 31, 2026; topline efficacy results are expected in the second half of 2027.

• R&D Spending Surges on Trial Costs

  Research and development expenses rose to $7.2 million in Q2 2026 from $1.3 million in Q2 2025, primarily due to costs associated with the C19 trial.

auto_awesomeAnalysis · NERV · Life Sciences

A $27.6 million non-cash gain from warrant liability revaluation drove Minerva Neurosciences to a GAAP net income of $17.5 million in Q2 2026, entirely masking an operating loss. The company ended the quarter with $75.4 million in cash and marketable securities, a position management believes funds operations for at least 12 months. R&D spending jumped to $7.2 million as the pivotal C19 trial for roluperidone enrolled its first patient in March 2026, with topline efficacy data expected in the second half of 2027. The warrant liability, a large balance-sheet item, decreased to $232.7 million from $278.6 million at the end of Q1, reflecting both exercises and fair-value changes. The company also disclosed that no shares have been sold under its $75 million at-the-market program established in May 2026.